Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Astellas, Medivation kick off TRUMPET
August 2015
SHARING OPTIONS:

NORTHBROOK, Ill. & SAN FRANCISCO—The first patients have been enrolled in TRUMPET (Treatment Registry for Outcomes in CRPC Patients), a prospective observational patient registry geared toward a better understanding of the needs and treatment patterns of patients with castration-resistant prostate cancer (CRPC), announced Astellas and Medivation Inc. recently. This registry will enroll and evaluate 2,000 patients with CRPC in addition to collecting data from the patients’ primary caregivers, including family and/or friends. The study will track patients and caregivers for up to six years, and the completion date is 2020. Collected information will include care patterns, treatment decisions and settings, physician referral patterns, quality-of-life outcomes and treatment satisfaction, as well as caregiver quality-of-life outcomes.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.